Author

Monica Ayine

University of Exeter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:protein structure prediction· 1 Approach:statistical model· 1

Frequent Co-Authors

Sebastian OlteaniD· 2 shared Angela C. ShoreiD· 1 shared Kim M. GoodingiD· 1 shared Martin StevensiD· 1 shared Megan StevensiD· 1 shared P Velbes Marqueti· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Sebastian OlteanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The apoptosis gene BCL-X splice isoforms have opposing effects in diabetic kidney disease: potential treatment target and prognostic value

Martin Stevens, Monica Ayine, Kim M. Gooding, Angela C. Shore, P Velbes Marqueti, Sebastian Oltean

The paper investigates the role of BCL-X splice isoforms in diabetic kidney disease, finding that increased BCL-XS promotes apoptosis and correlates with renal function decline, suggesting it as a biomarker and therapeutic target.

Journal of Diabetes Research · Jan 1, 2026Peer-reviewedMolecular Biology

Mechanistic analysis of compounds that modulate VEGF-A splicing in podocytes with therapeutic potential for diabetic nephropathy

Monica Ayine, Megan Stevens, Sebastian Oltean

This study identifies three compounds that increase VEGF-A165b expression in podocytes by modulating splicing through CLK1 kinase, suggesting CLK1 activation as a potential therapeutic strategy for diabetic nephropathy.

bioRxiv · Nov 27, 2025 · PreprintPharmacology & Toxicology